Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Hepatitis C
Interventions
Taribavirin, Ribavirin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Melanoma
Interventions
MK-3475, Peginterferon alfa-2b
Drug
Lead sponsor
Hassane M. Zarour, MD
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
105
States / cities
Birmingham, Alabama • Dothan, Alabama • Fresno, California + 86 more
Conditions
HIV Infections
Interventions
Peginterferon alfa-2b
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
0 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
21
States / cities
Berkeley, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 16 more
Conditions
Melanoma
Interventions
Decitabine, Pegylated Interferon Alpha-2b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hepatitis C
Interventions
Interferon-alpha
Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Tucson, Arizona • Atlanta, Georgia
Conditions
Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
Interventions
Pegylated Interferon alpha-2b, Capecitabine, 5-FU
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Conditions
HIV, HIV/AIDS
Interventions
Peg-IFN-α2b
Drug
Lead sponsor
The Wistar Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
adjuvant therapy, pegylated interferon alfa
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
Interventions
PEG -Intron, Colchicine
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 39 more
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
PEG-interferon alfa-2b, thalidomide
Biological · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Chronic Hepatitis C, Genotype 1
Interventions
Educational Intervention, Patient education and management skills training
Procedure · Other
Lead sponsor
Chronic Liver Disease Foundation
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
43
States / cities
Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more
Conditions
Hepatitis C
Interventions
Peginterferon-alpha-2b (PEG-Intron), Ribavirin, Epoetin-alpha (Procrit)
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
HIV, HIV/AIDS, HIV-1 Infection
Interventions
Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
Drug
Lead sponsor
Luis Montaner
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Hepatitis C Infection
Interventions
Boceprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Riverside, California
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more
Conditions
Chronic Hepatitis C
Interventions
albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
25
States / cities
Bakersfield, California • Pasadena, California • San Diego, California + 22 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PEG-interferon alfa-2b, temozolomide
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Lebanon, New Hampshire
Completed Phase 2 Interventional Results available

Study of PEG-Intron for Plexiform Neurofibromas

NCT00396019
Conditions
Plexiform Neurofibroma
Interventions
PEG-Intron
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Months to 21 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Chronic Hepatitis C
Interventions
Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
Drug
Lead sponsor
InterMune
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Brisbane, California
Conditions
Hepatitis, Chronic Active
Interventions
CPG10101, Control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more
Conditions
Adult T-cell Leukemia-Lymphoma, ATLL
Interventions
Belinostat, Zidovudine, Interferon-Alfa-2b, Pegylated Interferon-Alfa-2b, Lymphodepleting Therapy
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Miami, Florida
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Aldesleukin, Peginterferon alfa-2b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more